Researchers reported a novel RNA interference (RNAi) therapeutic that produced results consistent with a functional cure for chronic hepatitis B (HBV) in preclinical and early clinical evaluation, according to a Nature Communications report. The study demonstrates sustained declines in viral markers after treatment, including markers associated with cccDNA activity. The RNAi approach targets viral transcripts to reduce antigenemia and restore immune control, a strategy long sought by hepatology researchers. Authors highlighted the therapy’s ability to materially lower viral protein levels, which could enable combination regimens aiming for sustained off‑treatment responses; further clinical data and regulatory paths will determine its translational impact.